SHAREHOLDER ALERT: WeissLaw LLP Reminds FI, SVBI, FRPX, and PAND Shareholders About Its Ongoing Investigations

NEW YORK, March 18, 2021 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Frank's International N.V. FI

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Frank's International N.V. FI in connection with the proposed acquisition of the company by Expro Group ("Expro").  Under the terms of the merger agreement, Expro shareholders will receive 7.272 Frank's shares per Expro share they own.  Upon consummation of the transaction, the Company's shareholders will own approximately 35% of the combined entity, with Expro shareholders owning approximately 65%.  If you own FI shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslawllp.com/fi/

Severn Bancorp, Inc. SVBI

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Severn Bancorp, Inc. SVBI in connection with the proposed acquisition of the company by Shore Bancshares, Inc. ("Shore").  Under the terms of the merger agreement, Shore will acquire SVBI in a mixed cash-and-stock transaction, pursuant to which SVBI shareholders will receive $1.59 in cash and 0.6207 of a Shore common stock for each SVBI share that they own, representing implied per-share merger consideration of approximately $12.25 based upon Shore's March 17, 2021 closing price of $17.17.  If you own SVBI shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslawllp.com/svbi/

Five Prime Therapeutics, Inc. FPRX

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Five Prime Therapeutics, Inc. FPRX in connection with the proposed acquisition of the company by Amgen Inc.  The transaction is structured as an all-cash tender offer pursuant to which the company's shareholders will receive $38.00 for each share of FPRXcommon stock that they hold.   If you own FPRX shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslawllp.com/fprx/

Pandion Therapeutics, Inc. PAND

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Pandion Therapeutics, Inc. PAND in connection with the proposed all-cash acquisition of the company by Merck Sharp & Dohme Corp.  Under the terms of the merger agreement, PAND shareholders will receive $60.00 in cash for each share of PAND common stock that they own.  If you own PAND shares and wish to discuss this investigation or your rights, please call us or visit our website: https://www.weisslawllp.com/pand/

SOURCE WeissLaw LLP